 |
|
|
|
|
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Atara Biotherapeutics, Inc.
| | | | | Phone: | (646) 661-4588 | | Year Established: | 2012 | | Ticker: | ATRA | | Exchange: | NASDAQ | | Main Contact: | Isaac Ciechanover, Ph.D., President & CEO | | | | Other Contacts: | Utpal Koppikar, CFO
Dietmar Berger, M.D., Ph.D., Global Head, R&D
Heather D. Turner, Executive VP & General Counsel
Steve Bertram, Senior VP, Global HR
Gad Soffer, Executive VP & Chief Strategy Officer
Christopher Haqq, M.D., Ph.D., Executive VP, R&D & CSO
Kanya Rajangam, M.D., Ph.D., Senior VP & CMO
| | | | Company Description | | Atara is a biopharmaceutical development company focusing on innovative therapies for patients with debilitating diseases. Atara Bio's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. In September 2014, Atara Bio entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) under which it has the right to license (pursuant to a negotiated form of license agreement) the exclusive, worldwide rights to three clinical stage T-cell programs, as well as other T-cell programs that are discovered or developed by MSK pursuant to sponsored research funded by Atara Bio. | |
|
|
|
|
|
|
|
